Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Breast Neoplasms × Indocyanine Green × Clear all

Phase

Phase NA 12 Phase 2 11 Phase 3 2 Phase 4 1 Phase 2/3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lung Neoplasms 3 Neoplasms 2 Esophageal Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Suspected Central Nervous System Tumors 1 Stomach Neoplasms 1 Solitary Pulmonary Nodule 1 Multiple Pulmonary Nodules 1 Lymphedema 1 Head and Neck Neoplasms 1 Head and Neck Carcinoma 1 Giant Cell Tumor of Bone 1 Colorectal Neoplasms 1 Chylothorax 1 Breast Neoplasms 1

Interventions

Trastuzumab 56 Paclitaxel 54 Cyclophosphamide 38 pembrolizumab 31 Fulvestrant 29 Capecitabine 28 Carboplatin 26 Docetaxel 20 Letrozole 18 Doxorubicin 17 palbociclib 15 durvalumab 14 abemaciclib 14 pertuzumab 12 eribulin 11 Vinorelbine 11 Lapatinib 11 Gemcitabine 11 Filgrastim 11 Albumin-Bound Paclitaxel 11 ribociclib 10 Everolimus 10 Bevacizumab 10 Taxes 9 Radiotherapy 9 Peripheral Blood Stem Cell Transplantation 9 trastuzumab deruxtecan 8 olaparib 8 neratinib 8 fludarabine 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01993576 2014-10-15

EC2075

Jules Bordet Institute

Phase 1/2 Completed

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡